Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease
Authors:
- Edythe A. WiggsEWEdythe A. Wiggs
- Michael J. EblanMEMichael J. Eblan
- William BenkoWBWilliam Benko
- Shira G. ZieglerSZShira G. Ziegler
- Ellen SidranskyESEllen Sidransky
- Raphael SchiffmannRSRaphael Schiffmann
- 1 July 2008
- journal article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 153 (1) , 89-94.e4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- General measures of cognition for the preschool childMental Retardation and Developmental Disabilities Research Reviews, 2005
- Divergent phenotypes in Gaucher disease implicate the role of modifiersJournal of Medical Genetics, 2005
- Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3The Journal of Pediatrics, 2003
- Myoclonic Epilepsy in Gaucher Disease: Genotype-Phenotype Insights from a Rare Patient SubgroupPediatric Research, 2003
- New Prospects for the Treatment of Lysosomal Storage DiseasesDrugs, 2002
- Genotypic Heterogeneity and Phenotypic Variation among Patients with Type 2 Gaucher's DiseasePediatric Research, 1998
- Enzyme replacement treatment in type 1 and type 3 Gaucher's diseaseThe Lancet, 1994
- Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's diseaseNeurology, 1993
- Gaudier patients with oculomotor abnormalities do not have a unique genotypeClinical Genetics, 1992
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991